FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年10月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of October 9, with Northeast Electric (00042) leading at a premium of 743.75% [1][2]. AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042): 743.75% - Andeli Juice (02218): 235.25% - Zhejiang Shibao (01057): 227.36% [1][2] - The bottom three stocks with the lowest AH premium rates are: - Contemporary Amperex Technology (03750): -16.12% - Heng Rui Medicine (01276): -2.39% - China Merchants Bank (03968): 3.49% [1][2] Deviation Values - The stocks with the highest deviation values are: - Changfei Optical Fiber (06869): 28.93% - Zhejiang Shibao (01057): 12.23% - Red Star Macalline (01528): 11.20% [1][2] - The stocks with the lowest deviation values are: - Northeast Electric (00042): -72.24% - Shanghai Electric (02727): -54.73% - Dazhong Public Utilities (01635): -29.80% [1][2]

伴随着市场情绪回暖和政策层面释放积极信号，港股IPO市场呈现一片繁荣景象。 港交所数据显示，今年前9个月，港交所处理的上市申请数目（含重新申请企业）达380家，超过去年同期的两倍。 这些企业覆盖从医疗科技到消费服务、从新能源到人工智能等多个热门赛道，既折射出中国经济结构转型的新趋势，也反映出港股市场吸引力正强劲回 升。 今年港股IPO的热度离不开A股企业的积极参与。 在前9月的5宗"超大盘"交易中，有4宗为"A+H"股，包括宁德时代(03750.HK)、恒瑞医药(01276.HK)、三花智控(02050.HK)和海天味业(03288.HK)。 此外，Wind数据显示，今年前9月港股IPO（含创业板）募资总额约1823.97亿港元，同比大幅增长227.15%，显著高于美股，强势登顶全球IPO募资额榜 首。 IPO热潮推动"科技"含量持续提升 掀起本轮港股IPO市场热潮的推动力有四个方面：港交所持续优化上市制度、内地鼓励企业赴港上市、A股融资收紧以及美国对中概股监管持续加码。 这些因素共同促使更多优质企业转向香港资本市场。例如，在支持内地企业赴港上市方面，香港证监会和港交所此前推出了针对合资格A股公司的快速审 批 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 江蘇恒瑞醫藥股份有限公司 呈交日期: 2025年10月9日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01276 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 258,197,600 | RMB | | 1 RMB | | 258,197,600 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 258,197,600 | RMB | | 1 RMB | | 258,197,600 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

智通财经APP获悉，Global X中国生物科技ETF(02820) 8月份录得正回报。未来资产表示，在全球化主 题延续、国内政策支持、企业盈利改善及宏观环境向好的共同推动下，中国生物科技板块仍是年内表现 最佳的领域。近期重大对外授权交易彰显全球对中国企业创新质量的认可。我们发现过去两年对外授权 交易数量及首付款金额呈加速增长趋势，且创新药占比持续提升，表明中国原研资产进入美国/全球市 场正成为生物科技领域新常态。生物科技企业盈利改善和商业化进程加速，有望提振投资者对中国医疗 健康板块的情绪。 百济神州2025年第二季度业绩表现稳健：营收13亿美元（环比+18%），净利润9430万美元，双双超市 场预期。明星产品BRUKINSA（泽布替尼）的强劲销售势头（尤其在海外市场）推动当期利润率扩 张。公司同步上调了2025年营收指引下限和毛利率指引。（公司数据，2025 年 8 月） 江苏恒瑞医药（01276 ） 恒瑞医药8月公布的2025年第二季度业绩符合预期：当期营收86亿元人民币（同比+12.5%），药品销售 额约71亿元（同比+15%），较一季度11%的同比增速有所提升；净利润26亿元（同比+25%）。公司上 ...

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of October 8, with Northeast Electric (00042) leading at a premium of 730.77% and Ningde Times (03750) at the bottom with a premium of -17.12% [1][2]. AH Premium Rate Rankings - The top three stocks by AH premium rate are: - Northeast Electric (00042) with a premium of 730.77% [2] - Andeli Juice (02218) with a premium of 238.57% [2] - Zhejiang Shibao (01057) with a premium of 229.35% [2] - The bottom three stocks by AH premium rate are: - Ningde Times (03750) with a premium of -17.12% [2] - Heng Rui Medicine (01276) with a premium of -5.82% [2] - Chifeng Gold (06693) with a premium of -5.72% [2] Deviation Values - The top three stocks by deviation value are: - Red Star Macalline (01528) with a deviation of 20.62% [1] - Zhejiang Shibao (01057) with a deviation of 15.24% [1] - Junda Co., Ltd. (02865) with a deviation of 12.42% [1] - The bottom three stocks by deviation value are: - Northeast Electric (00042) with a deviation of -86.56% [1] - Dazhong Public Utilities (01635) with a deviation of -43.18% [1] - Shanghai Electric (02727) with a deviation of -41.15% [1]

智通财经APP获悉，截止10月6日收盘，东北电气(00042)、安德利果汁(02218)、浙江世宝(01057)分列 AH溢价率前三位，溢价率分别为815.25%、237.07%、231.95%；宁德时代(03750)、恒瑞医药(01276)、 紫金矿业(02899)分列AH溢价率末三位，溢价率分别为-19.28%、-7.05%、3.16%。其中红星美凯龙 (01528)、浙江世宝(01057)、长飞光纤光缆(06869)的偏离值位居前三，分别为25.18%、21.61%、 19.13%；另外，大众公用(01635)、上海电气(02727)、中芯国际(00981)的偏离值位居后三，分别 为-55.59%、-41.10%、-27.91%。 前十大AH股溢价率排行 前十大AH股偏离值排行 | 股票名称 | H股(港元) | | A股 | 溢价率 | | 偏离值↓ | | --- | --- | --- | --- | --- | --- | --- | | 红星美凯龙(01528) | 1.300 | 2.8 | | 157.69% | 25.18% | | | 浙江世宝(01057) | 5.070 | 14. ...

Core Viewpoint - The company has received a drug registration application acceptance notice from the National Medical Products Administration for its innovative drug, injection Karilizumab combined with Apalutamide capsules, for first-line treatment of recurrent or metastatic cervical cancer patients [1] Drug Information - Drug Names: Injection Karilizumab (injection) and Apalutamide capsules (capsule) [1] - The application is based on a Phase III clinical study comparing Karilizumab combined with Apalutamide to platinum-based chemotherapy for recurrent or metastatic cervical cancer [1] - The study was led by Professor Wu Xiaohua from Fudan University Shanghai Cancer Center, involving 45 domestic centers and enrolling 443 patients [1] - The study achieved its primary endpoint by July 2025, demonstrating that the experimental group significantly outperformed the control group in terms of progression-free survival (PFS) and overall survival (OS) [1] - The results confirm the efficacy and safety of Karilizumab combined with Apalutamide as a first-line treatment for recurrent or metastatic cervical cancer patients [1]

Core Viewpoint - Heng Rui Medicine (01276) has received a drug registration application acceptance notice from the National Medical Products Administration for its innovative drug, injection Karilizumab combined with Apalutamide capsules, for first-line treatment of recurrent or metastatic cervical cancer patients [1] Group 1: Drug Development - The application for market approval is based on a Phase III clinical study comparing Karilizumab combined with Apalutamide against platinum-based chemotherapy for recurrent or metastatic cervical cancer [1] - The study was led by Professor Wu Xiaohua from Fudan University Shanghai Cancer Center, involving 45 domestic centers and enrolling 443 patients [1] - The study achieved its primary endpoint by July 2025, demonstrating that the experimental group significantly outperformed the control group in terms of progression-free survival (PFS) and overall survival (OS) [1] Group 2: Efficacy and Safety - The results confirm the efficacy and safety of Karilizumab combined with Apalutamide as a first-line treatment for patients with recurrent or metastatic cervical cancer [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of HRS-2329 tablets, an innovative anti-tumor drug targeting late-stage solid tumors with RAS mutations or amplifications [1] Drug Information - Drug Name: HRS-2329 Tablets [1] - Dosage Form: Tablets [1] - Application Matter: Clinical Trial [1] - Acceptance Numbers: CXHL2500682, CXHL2500683, CXHL2500684 [1] - Approval Conclusion: The clinical trial application for HRS-2329 tablets, accepted on July 10, 2025, meets the requirements for drug registration and is approved for trials in patients with late-stage solid tumors carrying RAS mutations or amplifications [1] Development Status - HRS-2329 tablets are independently developed by the company and have shown good anti-tumor activity in preclinical animal models [1] - The drug is intended for the treatment of late-stage solid tumors with RAS mutations or amplifications [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] - The cumulative R&D investment for the HRS-2329 project is approximately 60.15 million yuan [1]